Bernstein Liebhard LLP Applauds Calls For Increased Scrutiny Of Transvaginal Mesh

Bernstein Liebhard LLP supports the FDA advisory panel’s calls for tougher restrictions and more clinical trials for transvaginal mesh implants, which are used to repair pelvic organ prolapse. After evaluating reports and trials on vaginal mesh complications, the panel concluded that a reclassification is appropriate. New York, NY (PRWEB) September 09, 2011 Bernstein Liebhard LLP is excited to report on the outcome of yesterday’s meeting of the Obstetrics and Gynecology Devices advisory panel to the U.S. Food and Drug Administration (“FDA”).* The advisory panel supported the FDA’s propose
Contributor
About
PRWeb, a leader in online news and press release distribution, has been used by attorneys, law firms and more than 40,000 organizations